Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-10-06
2011-10-04
Solola, Taofiq A (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S209000
Reexamination Certificate
active
08030331
ABSTRACT:
The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1and R2are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
REFERENCES:
patent: 3991064 (1976-11-01), Brown et al.
patent: 7834035 (2010-11-01), Bessis et al.
patent: 2002/0077337 (2002-06-01), Rigby et al.
patent: 2003/0149049 (2003-08-01), Arkin et al.
patent: 950872 (1964-02-01), None
patent: WO-91/04250 (1991-04-01), None
patent: WO-99/02497 (1999-01-01), None
patent: WO-00/25768 (2000-05-01), None
patent: WO-01/02375 (2001-01-01), None
patent: WO-01/54498 (2001-08-01), None
patent: WO-01/54507 (2001-08-01), None
patent: WO-03/027080 (2003-04-01), None
patent: WO-03/037888 (2003-05-01), None
patent: WO-03/066595 (2003-08-01), None
patent: WO-2004/011441 (2004-02-01), None
patent: WO-2004/014902 (2004-02-01), None
patent: WO-2004/029031 (2004-04-01), None
patent: WO-2004/038374 (2004-05-01), None
patent: WO-2004/052864 (2004-06-01), None
patent: WO-2004/058754 (2004-07-01), None
patent: WO-2004/085408 (2004-10-01), None
patent: WO-2004/087048 (2004-10-01), None
Rogers, et al., Neurobiology of Aging, vol. 17, No. 5, pp. 681-686 (1996).
Yan, et al., J. Comb. Chem., vol. 5, No. 5, pp. 547-559 (2003).
Phillips, et al., J. Med. Chem., vol. 35, No. 4, pp. 743-750 (1992).
Toja, E. et al., Farmaco Sci., vol. 39, No. 5, pp. 450-462 (1984).
CAS Registry No. 695195-63-2, Chemical Library, Supplier: Chemical Block Ltd, CAS Registry (2004).
Opposition (brief) filed in the name of Sanofi-Aventis in corresponding European Patent No. 1 685 105 Bl, dated Jul. 20, 2009.
Opposition (brief) filed in the name of Dr. Thorsten Bausch in corresponding European Patent No. 1 685 105 B1, dated Jul. 14, 2009.
Baker et al., Journal of Organic Chemistry, 17:52-57, XP002321098 (1952).
Eastman et al., Bioorganic and Medicinal Chemistry Letters, 14:5485-5488, XP002321099 (2004).
Bessis Anne-Sophie
Bonnet Beatrice
Epping-Jordan Mark
Le Poul Emmanuel
Rocher Jean-Philippe
Addex Pharma SA
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Russett Mark D.
Solola Taofiq A
LandOfFree
Allosteric modulators of metabotropic glutamate receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Allosteric modulators of metabotropic glutamate receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allosteric modulators of metabotropic glutamate receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4302604